Login
Cara Therapeutics NASDAQ: CARA
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to fundamentally change the way acute pain, chronic pain and pruritus are managed
| Name | Cara Therapeutics |
| Ticker | CARA |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Cannabinoid Therapeutics |
| Price | 13.22 |
| 52W Low/High | 9.12 / 25.98 |
| Market cap | 619 M |
| 1Y Total Return |
-35.07%
Below Average |
| 1Y Volatility |
73.53%
More Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to fundamentally change the way acute pain, chronic pain and pruritus are managed
Details
| Ticker | CARA |
| Name | Cara Therapeutics |
| ISIN | US1407551092 |
| CUSIP | 140755109 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Cannabinoid Therapeutics |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 10/28/20
| Close Price | 13.22 |
| 52W Low/High | 9.12 / 25.98 |
| Market cap | 619 M |
| 1Y Total Return |
-35.07%
Below Average |
| 1Y Volatility |
73.53%
More Risk |
| Beta | 2.09 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -480.6% |
| Cash from Op. / Cur. Liabilities | -4.96 |
| Diluted Earnings / Share | -2.51 |
| ROE | - |
| ROIC | -130.3% |
| Price / Revenue | 25.8 |
| Price / Book | 4.4 |
| Price / CF | -5.0 |
| Current Ratio | 5.7 |
| Cur.Liabilities / Tot.Liabilities | 0.9 |
| Financial Leverage | 0.03 |
| in Mils USD |
rolling-year up to June
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
24
|
20
|
3
|
1
|
3
|
3
|
|
| Gross Profit |
24
|
20
|
3
|
1
|
3
|
3
|
|
| R&D |
126
|
93
|
51
|
58
|
32
|
18
|
|
| EBITDA |
-115
|
-85
|
-60
|
-65
|
-37
|
-21
|
|
| Operating Income |
-120
|
-90
|
-62
|
-66
|
-39
|
-21
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
47
|
40
|
33
|
32
|
27
|
23
|
|
| EPS exc. Extra |
-2.51
|
-2.17
|
-1.84
|
-2.33
|
-1.42
|
-0.93
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
169
|
150
|
140
|
118
|
92
|
46
|
|
| Cash, Eq & Invt ShortTerm |
131
|
116
|
133
|
114
|
86
|
44
|
|
| Total Current Assets |
142
|
125
|
139
|
116
|
89
|
44
|
|
| Total Non-Current Assets |
27
|
25
|
1
|
2
|
3
|
2
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
28
|
50
|
67
|
9
|
9
|
4
|
|
| Total Current Liabilities |
25
|
40
|
35
|
7
|
8
|
3
|
|
| Long Term Debt |
3
|
10
|
32
|
2
|
1
|
1
|
|
| Shareholder equity |
141
|
100
|
73
|
109
|
83
|
42
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-123
|
-97
|
1
|
-60
|
-33
|
-20
|
|
| Depreciation |
1
|
1
|
0
|
0
|
2
|
1
|
|
| Cash from Investing |
22
|
-1
|
-10
|
-21
|
-82
|
0
|
|
| Capex |
0
|
0
|
0
|
1
|
0
|
0
|
|
| Cash from Financing |
139
|
99
|
17
|
88
|
76
|
0
|
|
| Stock Issued |
139
|
99
|
17
|
88
|
76
|
0
|
|
| Debt (LT) Issued |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Free Cash Flow |
-107
|
-66
|
-44
|
-87
|
-113
|
-22
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
5.7
|
3.1
|
4.0
|
16.1
|
10.9
|
13.6
|
|
| Financial Leverage D/E |
0.03
|
0.05
|
0.00
|
0.00
|
0.00
|
0.00
|
|
| Return on Capital Avg |
-130.3%
|
-95.9%
|
-65.0%
|
-72.5%
|
-96.2%
|
-
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available